Amendments to the Specification:

Please replace the list of inventors on the cover page with the following

Inventors:

GLENN H. MCGALL, a citizen of Canada, residing at 750 North Shoreline, Mountain View, California 94041;

ANTHONY D. BARRONE, a citizen of the United States of America, residing at 2118 Ellen Avenue, San Jose, CA 95125

Please replace the cross-reference to related applications on page 1 with the following rewritten paragraph:

This is a continuation of U.S. Application No. 08/882,649, filed June 25, 1997, now U.S. Patent No. 6,344,316, which is a continuation of PCT/US97/01603, filed on January 22, 1997, designating the United States of America, which derives priority from USSN 60/010,471 filed January 23, 1996 and USSN 60/035,170, filed January 9, 1997, all of which are herein incorporated by reference for all purposes.

Please replace the paragraph beginning at page 18, line 3 with the following amended paragraph:

Figs. 14a, 14b, 14c, and 14d illustrates a ligation discrimination used in conjunction with a restriction digest of the sample nucleic acid. FIG. 14a shows the recognition site and cleavage pattern of SacI (a 6 cutter) and Hsp92II (4 cutter). FIG. 14b illustrates the effect of SacI cleavage on a (target) nucleic acid sample. FIG. 14c illustrates a 6 Mb genome (i.e., E. coli) digested with SacI and SphI generating .about.1 kb genomic fragments with a 5' C. FIG. 14d illustrates the hybridization/ligation of these fragments to a generic difference screening chip and their subsequent use as probes to hybridize to the appropriate nucleic acid (Format I) or the fragments are labeled, hybridized/ligated to the [[oligonucletide array]] oligonucleotide array and directly analyzed (Format II).

Please replace the paragraph beginning at page 18, line 12 with the following amended paragraph:

Appl. No. 09/880,727
Amdt. dated January 23, 2004
Reply to Office Action of November 24, 2003

PATENT

Figs. 15a, 15b, 15c, 15d, and 15e illustrate the analysis of [[differntial display]] differential display DNA fragments on a generic difference [[screening]] screening array. Fig. 15a shows first strand cDNA synthesis (SEQ ID NO:7) by reverse [[transcripton]] transcription of poly(a) mRNA using an anchored poly(T) primer (SEQ ID NO:8). Fig. 15b illustrates upstream primers for PCR reaction containing an engineered [[restrictionsite]] restriction site and degenerate bases (N=A,G,C,T) at the 3' end. Fig. 15c shows randomly primed PCR of first strand cDNA. Fig. 15d shows [[restrictiondigest]] reaction digest of PCR products, and Fig. 15e shows sorting of PCR products on a generic [gligationarray] ligation array by their [[5'end]] 5' end.

Please replace the paragraph beginning at page 19, line 4 with the following amended paragraph:

Fig. 19 provides a schematic illustration of pos-hybridization end labeling (SEQ ID NO:9) on a high density oligonucleotide array.

Please replace the paragraph beginning at page 19, line 10 with the following amended paragraph:

Fig. 22 illustrates oligo dT labeling on a high density oligonucleotide array (SEQ ID NOS:10 and 11).

Please replace the paragraph beginning at page 19, line 15 with the following amended paragraph:

Fig. 24. illustrates resequencing of a target DNA molecule with a set of generic n-mer tiling probes (target sequence is SEQ ID NO:12).

Please replace the paragraph beginning at page 19, line 26 with the following amended paragraph:

Fig. 32 illustrates mutations found in an HIV PCR target (B) using a generic ligation GeneChip™ and induced difference analysis (SEQ ID NOS:13-32 respectively).

Appl. No. 09/880,727
Amdt. dated January 23, 2004
Reply to Office Action of November 24, 2003

PATENT

Please replace the paragraph beginning at page 57, line 12 with the following amended paragraph:

If any probe failed one of these criteria (1-8), the probe was not a member of the subset of probes placed on the chip. For example, if a hypothetical probe was 5'-AGCTTTTTTCATGCATCTAT-3' (SEQ ID NO:1) the probe would not be synthesized on the chip because it has a run of four or more bases (*i.e.*, run of six).

Please replace the paragraph beginning at page 58, line 28 with the following amended paragraph:

The simplest pruning method is to line up a proposed probe with all known genes for the organism being monitored, then count the number of matching bases. For example, given a probe (SEQ ID NO:2) to gene 1 of an organism and gene 2 (SEQ ID NO:3) of an organism as follows:

```
probe from gene 1: aagcgcgatcgattatgctc
                   |      |||||||
      gene 2:      atctcggatcgatcggataagcgcgatcgattatgccggcga
```

has 8 matching bases in this alignment, but 20 matching bases in the following alignment:

```
probe from gene 1:                  aagcgcgatcgattatgctc
                                    ||||||||||||||||||||
      gene 2:      atctcggatcgatcggataagcgcgatcgattatgccggcga
```

Please replace the paragraph beginning at page 81, line 1 with the following amended paragraph:

The principle behind differential display is to [[generat]] generate a set of randomly primed amplification (*e.g.*, PCR) fragments from a first strand cDNA population transcribed from RNA using anchor primers of the form:

$$(T)_nVA, (T)_nVG, (T)_nVC, \text{ and } (T)_nVT \quad \text{(SEQ ID NO:4)}$$

Appl. No. 09/880,727
Amdt. dated January 23, 2004
Reply to Office Action of November 24, 2003

PATENT

in which V is A, G, or C, and n ranges from about 6 to about 30, preferably from about 8 to about 20 and more preferably about 10 to about 16 with n=14 being most preferred. Depending on what random primer and anchoring primer [and anchoring proimer] is chosen, different sets of cDNA transcripts are represented in a particular nucleic acid fragment set. These amplification fragments are analyzed by sorting the fragments on a generic screening oligonculeotide array where they hybridize based on the sequence at the 5' end of the [[fragement]] fragment.

Please replace the paragraph beginning at page 139, line 11 with the following amended paragraph:

The following 5' sequence (SEQ ID NO:5) has worked well (with 19-21 gene-specific bases added at the 3' end).

5'-GAATTGTAATACGACTCACTATAGGGAGG-[+19-21 gene specific bases]-3'

The 5' end consists of:

a)   six 5' flanking bases of your choice – not part of the promoter sequence, but necessary for maximum IVT efficiency.

b)   17 bases of the core T7 RNA polymerase promoter sequence

c)   1st 6 bases transcribed (sequence of +1 to +6 can affect efficiency)

The other PCR primer would then contain the T3 RNA polymerase promoter sequence at the 5' end. The following sequence (SEQ ID NO:6) has worked well:

5'-AGATGCAATTAACCCTCACTAAAGGGAGA-(+19-21 gene-specific bases)-3'

The 5' end consists of:

Appl. No. 09/880,727
Amdt. dated January 23, 2004
Reply to Office Action of November 24, 2003

PATENT

    a)   six 5' flanking bases (sequence can vary from this example)

    b)   17 bases of core T3 RNA Polymerase promoter sequence

    c)   +1 to +6 transcribed bases